KR950031089A - 경비 투여가능한 조성물 - Google Patents

경비 투여가능한 조성물 Download PDF

Info

Publication number
KR950031089A
KR950031089A KR1019950011608A KR19950011608A KR950031089A KR 950031089 A KR950031089 A KR 950031089A KR 1019950011608 A KR1019950011608 A KR 1019950011608A KR 19950011608 A KR19950011608 A KR 19950011608A KR 950031089 A KR950031089 A KR 950031089A
Authority
KR
South Korea
Prior art keywords
calcium
composition
aluminum
magnesium
compound
Prior art date
Application number
KR1019950011608A
Other languages
English (en)
Other versions
KR100329249B1 (ko
Inventor
아끼라 야나가와
Original Assignee
야나가와 히로미
유우겡가이샤 돗뜨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야나가와 히로미, 유우겡가이샤 돗뜨 filed Critical 야나가와 히로미
Publication of KR950031089A publication Critical patent/KR950031089A/ko
Application granted granted Critical
Publication of KR100329249B1 publication Critical patent/KR100329249B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

특정한 담체상에 균질하게 분산시키고 균질하게 흡착시킨 생리적 활성 물질을 함유하는 경비 투여가능한 조성물. 경비 투여가능한 조성물은 생리적 허용가능한 분말 또는 결정성 다가 금속 화합물 담체상에 균질하게 분산시키고 균질하게 흡착시킨 분자량 40,000 이하인 생리적 활성 물질의 생리적 유효량을 함유한다.
금속 화합물 담체는 알루미늄 화합물, 칼슘 화합물, 마그네슘 화합물, 규소 화합물, 철 화합물 및 아연 화합물에서 선택된다.
조성물은 경비 투여가능한 분말상이다.

Description

경비 투여가능한 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (26)

  1. 분자량 40,000이하인 생리적 활성 물질 및 생리적 허용가능한 분말 또는 결정성 다가 금속 담체를 함유하고, 평균 입자 크기 250μm 이하인 다가 금속 담체상에 생리적 활성 물질의 유효량을 균질하게 분산시키고 균질하게 흡착시킴을 특징으로 경비 투여가능한 조성물.
  2. 제1항에 있어서, 다가 금속 담체가 알루미늄 화합물, 칼슘 화합물, 마그네슘 화합물, 규소 화합물, 철 화합물 및 아연 화합물로 구성된 군에서 선택된 2가 금속 화합물임을 특징으로 하는 조성물.
  3. 제2항에 있어서, 알루미늄 화합물이 건조 알루미늄 히드록시 젤, 알루미늄 히드록시클로라이드, 합성 알루미늄 실리케이트, 광 알루미늄 산화물, 콜로이드성 알루미늄 실리케니트 수화물, 알루미늄 마그네슘 히드록시드, 알루미늄 히드록시드, 알루미늄 히드록시드 젤, 알루미늄 술페이트, 디히드록시알루미늄 아미노아세테이트, 알루미늄 스테아레이트, 천연 알루미늄 실리케이트, 알루미늄 모노스테아레이트 및 칼슘 알루미늄 술페이트로 구성된 군에서 선택됨을 특징으로하는 조성물.
  4. 제2항에 있어서, 칼슘 화합물이 아파타이트, 히드록시아파타이트, 칼슘카르보네이트, 칼슘 디소듐 EDTA, 칼슘 클로라이드, 칼슘 시트레이트, 칼슘 글리세로포스페이트, 칼슘 글루코네이트, 칼슘 실리케이트, 칼슘 옥시드, 칼슘 히드록시드, 칼슘 스테아레이트, 3염기 인산 칼슘, 칼슘 락테이트, 칼슘 판토테네이트, 칼슘 올레에이트, 칼슘 팔미테이트, 칼슘 D-판토테네이트, 칼슘 알기네이트, 칼슘 포스페이트, 무수물, 칼슘 수소포스페이트, 칼슘 제1인산염, 칼슘 아세테이트, 칼슘 사카레이트, 칼슘 술페이트, 칼슘 제2인산염, 칼슘 파라-아미노살리실레이트, 및 바이오 칼시루타이트 화합물로 구성된 군에서 선택됨을 특징으로 하는 조성물.
  5. 제2항에 있어서, 마그네슘 화합물이 마그네슘 L-아스파르테이트, 마그네슘 클로라이드, 마그네슘 클루코네이트, 마그네슘 알루미네이트 실리케이트, 마그네슘 실리케이트, 마그네슘 옥시드, 마그네슘 히드록시드, 마그네슘 스테아레이트, 마그네슘 카르보네이트, 마그네슘 알루미네이트 메타실리케이트, 마그네슘 술페이트, 소듐 마그네슘 실리케이트 및 합성 소듐 마그네슘 실리케이트로 구성된 군에서 선택됨을 특징으로 하는 조성물.
  6. 제2항에 있어서, 규소 화합물이 산화규소 수화물, 경규소 무수물, 합성 히드로탈사이트, 규조토 및 이산화규소로부터 선택됨을 특징으로 하는 조성물.
  7. 제2항에 있어서, 철 화합물이 황산철(II)임을 특징으로 하는 조성물.
  8. 제2항에 있어서, 아연 화합물이 염화아연, 아연 스테아레이트, 산화아연 및 황산아연임을 특징으로 하는 조성물.
  9. 제4항에 있어서, 칼슘 화합물이 히드록시아파타이트, 칼슘 카르보네이트 또는 칼슘 락테이트임을 특징으로 하는 조성물.
  10. 제5항에 있어서, 마그네슘 화합물이 마그네슘 스테아레이트임을 특징으로 하는 조성물.
  11. 제3항에 있어서, 알루미늄 화합물이 알루미늄 히드록시드임을 특징으로 하는 조성물.
  12. 제1항 내지 제11항 중 어느 한 항에 있어서, 다가 금속 담체가 평균 입자 크기 100μm 이하임을 특징으로 하는 조성물.
  13. 제12항에 있어서, 다가 금속 담체의 평균 입자 크기가 30μm∼60μm임을 특징으로하는 조성물.
  14. 제1항에 있어서, 분자량 40,000 이하인 생리적 활성 물질이 생리적 활성 펩티드, 수면제 및 진정제, 항간질약제, 부신경안정제, 주신경안정제, 항우울제, 근육 이완제, 항알러지제, 항류마티즘제, 강심제, 항부정맥제, 고혈압 방지 이뇨제, α-차단제, β-아드레날린성 차단제, 칼슘 통로 길항제, 안지오텐신 전환 효소저해제, 혈압강하제, 관상 혈관확장제, 대뇌순환 및 물질 대사 개선제, 동맥경화방지제, 심혈관제, 기관지확장제, 항궤양제, 진토약제, 비만방지제, 혈소판 응집 저해제, 당뇨병 치료제/당뇨 증상 치료제, 부신 피질 호르몬, DNA/RNA 화합물로 구성된 군에서 선택됨을 특징으로 하는 조성물.
  15. 제14항에 있어서, 생리적 활성 물질이 생리적 활성 펩티드임을 특징으로 하는 조성물.
  16. 생리적 활성 펩티드 및 생리적 허용가능한 분말 또는 결정성 다가 금속 담체를 함유하고, 평균 입자 크기 250μm 이하인 다가 금속 담체상에 생리적 활성 펩티드의 생리적 유효량을 균질하게 분산시키고, 균질하게 흡착시킴을 특징으로 하는 경비 투여가능한 조성물.
  17. 제16항에 있어서, 다가 금속 담체가 제2항에 정의된 화합물로부터 선택된 2가 금속 화합물의 하나임을 특징으로 하는 조성물.
  18. 제17항에 있어서, 다가 금속 담체가 제3항 내지 제8항 중 어느 한 항에 정의된 담체의 하나임을 특징으로 하는 조성물.
  19. 제17항에 있어서, 담체의 평균 입자 크기가 100μm 이하임을 특징으로 하는 조성물.
  20. 제19항에 있어서, 담체의 평균 입자 크기가 30μm∼60μm임을 특징으로 하는 조성물.
  21. 제16항에 있어서, 생리적 활성 펩티드가 펩티드 호르몬, 생리적 활성 단백질 또는 효소 단백질임을 특징으로하는 조성물.
  22. 제21항에 있어서, 펩티드 호르몬이 칼시토닌, 인슐린, 글루카곤 및 소마트로핀(성장 호르몬)에서 선택됨을 특징으로 하는 조성물.
  23. 제22항에 있어서, 히드록시아파타이트, 칼슘 카르보네이트, 칼슘 락테이트, 마그네슘 스테아레이트 및 알루미늄 히드록시로 구성된 군에서 선택되고, 평균 입자 크기 30μm∼60μm인 담체상에 칼시토닌을 균질하게 분산시키고 균질하게 흡착시킴을 특징으로 하는 조성물.
  24. 제22항에 있어서, 히드록시아파타이트, 칼슘 카르보네이트, 칼슘 락테이트, 마그네슘 스테아레이트 및 알루미늄 히드록시로 구성된 군에서 선택되고, 평균 입자 크기 30μm∼60μm인 담체상에 인슐린을 균질하게 분산시키고 균질하게 흡착시킴을 특징으로 하는 조성물.
  25. 제22항에 있어서, 히드록시아파타이트, 칼슘 카르보네이트, 칼슘 락테이트, 마그네슘 스테아레이트 및 알루미늄 히드록시로 구성된 군에서 선택되고, 평균 입자 크기 30μm∼60μm인 담체상에 글리카곤을 균질하게 분산시키고 균질하게 흡착시킴을 특징으로 하는 조성물.
  26. 제22항에 있어서, 히드록시아파타이트, 칼슘 카르보네이트, 칼슘 락테이트, 마그네슘 스테아레이트 및 알루미늄 히드록시로 구성된 군에서 선택되고, 평균 입자 크기 30μm∼60μm인 담체상에 소파트로핀을 균질하게 분산시키고 균질하게 흡착시킴을 특징으로 하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950011608A 1994-05-11 1995-05-11 경비 투여 가능한 조성물 KR100329249B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP12077894 1994-05-11
JP94-120778 1994-05-11
JP95-66640 1995-03-02
JP06664095A JP3414539B2 (ja) 1994-05-11 1995-03-02 経鼻吸収用組成物

Publications (2)

Publication Number Publication Date
KR950031089A true KR950031089A (ko) 1995-12-18
KR100329249B1 KR100329249B1 (ko) 2002-09-27

Family

ID=26407838

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950011608A KR100329249B1 (ko) 1994-05-11 1995-05-11 경비 투여 가능한 조성물

Country Status (8)

Country Link
US (1) US5603943A (ko)
EP (1) EP0681833B1 (ko)
JP (1) JP3414539B2 (ko)
KR (1) KR100329249B1 (ko)
CN (1) CN1076624C (ko)
AT (1) ATE201982T1 (ko)
DE (1) DE69521239T2 (ko)
ES (1) ES2158012T3 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100529244B1 (ko) * 2002-11-30 2005-11-17 이은미 비만 치료를 위한 한약재 용액 및 랩

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5858408A (en) * 1994-07-20 1999-01-12 Toyama Chemical Co., Ltd. Sustained-release oral ointment
CA2192576A1 (en) * 1995-04-24 1996-10-31 Fuminori Tokumochi Remedy for allergic diseases in the region of the nose
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
DE69719367T2 (de) * 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
BR9808285A (pt) * 1997-03-20 2000-05-16 Novo Nordisk As Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus
IT1291559B1 (it) * 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
US20060239930A1 (en) * 1997-08-04 2006-10-26 Herbert Lamche Process for nebulizing aqueous compositions containing highly concentrated insulin
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6159968A (en) * 1998-01-15 2000-12-12 University Of Cincinnati Activation of chloride channels for correction of defective chloride transport
AR019025A1 (es) * 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
EP1083931B1 (en) * 1998-06-05 2005-05-11 Warner-Lambert Company LLC Stabilization of compositions containing ace inhibitors using magnesium oxide
KR100359716B1 (ko) * 1998-09-11 2003-04-21 (주)나노하이브리드 유전자의보관및전달이가능한생-무기하이브리드복합체및그의제조방법
DK1146906T3 (da) * 1999-02-05 2011-10-24 Alk Abello As Mukosalt afgivelsessystem
US6706732B1 (en) 1999-06-03 2004-03-16 Takeda Chemical Industries, Ltd. Nasal preparation of guanidinoimino quinoline derivatives
RU2271196C2 (ru) * 1999-06-04 2006-03-10 Элзэ Копэрейшн Имплантируемая композиция (варианты) и способ ее приготовления
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
WO2001049869A1 (fr) * 1999-12-30 2001-07-12 Aventis Pharma S.A. Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires
FR2803206A1 (fr) * 1999-12-30 2001-07-06 Aventis Pharma Sa Composition comprenant des acides nucleiques, preparation et utilisation
BR0107764A (pt) * 2000-01-20 2002-11-12 Basilea Pharmaceutica Ag Composições de peptìdeo cìclico nasalmente administráveis
JP2001316286A (ja) * 2000-05-02 2001-11-13 Dds Kenkyusho:Kk インスリンの経鼻吸収用製剤
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20020051794A1 (en) * 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
JP2002348234A (ja) * 2001-05-28 2002-12-04 Purotekku:Kk 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤
KR100427638B1 (ko) * 2001-06-21 2004-04-28 한불화장품주식회사 안정화된 효소 결합체 조성물 및 이를 함유하는 화장료
WO2003015800A1 (en) * 2001-08-09 2003-02-27 Ivoclar Vivadent, Inc. Tissue implants and methods for making and using same
US20050014681A1 (en) * 2001-11-26 2005-01-20 Yoshiharu Minamitake Medicinal compositions for nasal absorption
CN1674903A (zh) * 2002-07-11 2005-09-28 大鹏药品工业株式会社 经鼻吸收用组合物
JP2004043479A (ja) * 2002-07-11 2004-02-12 Taiho Yakuhin Kogyo Kk 経鼻吸収用組成物
US7885708B2 (en) * 2003-01-15 2011-02-08 Erchonia Corporation Iontophoresis device
PT1587514E (pt) * 2003-01-31 2006-09-29 Orexo Ab Composicao farmaceutica de accao rapida
KR20030036302A (ko) 2003-02-26 2003-05-09 엘지전자 주식회사 공기조화기용 벽 매입형 실외기
JP4493594B2 (ja) * 2003-03-04 2010-06-30 田辺三菱製薬株式会社 粉末経鼻投与製剤
US20040241100A1 (en) * 2003-03-17 2004-12-02 Fabre Kramer Pharmaceutical, Inc. Nasally administrable compositions of zolpidem and methods of use
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20040219229A1 (en) * 2003-04-30 2004-11-04 Tim Clarot Migraine relief composition and methods of using and forming same
WO2004113332A1 (ja) * 2003-06-19 2004-12-29 Ono Pharmaceutical Co., Ltd. 経鼻製剤
NZ545086A (en) 2003-08-07 2011-06-30 Healor Ltd Pharmaceutical compositions and methods for accelerating wound healing
GB0329918D0 (en) 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
EP1719527B1 (en) * 2004-02-09 2016-05-04 Kabushiki Kaisha Sangi Antitumor agents
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
CA2522152A1 (en) * 2004-10-07 2006-04-07 Kabushiki Kaisha Sangi Transdermal and transmucosal preparations
EP1872798B1 (en) 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
CN101229378A (zh) * 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
CA2625674C (en) * 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
US9358242B2 (en) * 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
BRPI1014783A2 (pt) * 2009-03-26 2018-06-12 Pulmatrix Inc formulações farmacêuticas e métodos para tratar infecções do trato respiratório
CN102448439A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
JP5663750B2 (ja) 2009-09-30 2015-02-04 株式会社サンギ 難溶性物質の水溶解性改善方法
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
EP2504052B1 (en) 2009-11-25 2022-07-27 Boehringer Ingelheim International GmbH Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011083482A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of psoriasis
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012044736A1 (en) 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
CA2889552C (fr) 2012-11-13 2023-10-10 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
DK3139984T3 (da) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Forstøver
EP3139979B1 (en) 2014-05-07 2023-07-05 Boehringer Ingelheim International GmbH Unit, nebulizer and method
HUE058904T2 (hu) 2014-05-07 2022-09-28 Boehringer Ingelheim Int Porlasztókészülék
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
PT3242676T (pt) 2015-01-07 2023-12-06 TONIX Pharmaceuticals Holding Corp Formulações de ocitocina que contém magnésio e métodos de uso
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
CN111278425A (zh) * 2017-09-11 2020-06-12 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5284423A (en) * 1976-01-06 1977-07-14 Mitsubishi Electric Corp Invertor protection device
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPH05206922A (ja) * 1992-01-27 1993-08-13 Nec Corp カード型個別呼出用受信機
JPH05255095A (ja) * 1992-03-13 1993-10-05 Advance Co Ltd 血管内投与剤
KR940006601A (ko) * 1992-09-12 1994-04-25 야나가와 히로미 생리활성 펩티드 조성물
JPH07165613A (ja) * 1993-10-19 1995-06-27 Dot:Kk 経鼻吸収薬物用キャリヤおよび生理活性ペプチド組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100529244B1 (ko) * 2002-11-30 2005-11-17 이은미 비만 치료를 위한 한약재 용액 및 랩

Also Published As

Publication number Publication date
JPH0827031A (ja) 1996-01-30
CN1117874A (zh) 1996-03-06
JP3414539B2 (ja) 2003-06-09
EP0681833B1 (en) 2001-06-13
DE69521239D1 (de) 2001-07-19
ES2158012T3 (es) 2001-09-01
DE69521239T2 (de) 2001-09-20
US5603943A (en) 1997-02-18
CN1076624C (zh) 2001-12-26
EP0681833A2 (en) 1995-11-15
KR100329249B1 (ko) 2002-09-27
EP0681833A3 (en) 1996-04-17
ATE201982T1 (de) 2001-06-15

Similar Documents

Publication Publication Date Title
KR950031089A (ko) 경비 투여가능한 조성물
Jin et al. Supragingival calculus: formation and control
Jurkić et al. Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy
Schachter et al. Active transport of calcium by intestine: action and bio-assay of vitamin D
Rehman et al. The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers
Yu et al. Nutritional influences on aging of Fischer 344 rats: I. Physical, metabolic, and longevity characteristics
Levenson et al. A review of calcium preparations
JP2001517633A5 (ko)
US20150209249A1 (en) Enhanced Anti-Carious Dentifrices, Rinses, Lozenges, Candies and Chewing Gums and Methods of Using Same
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
Nusynowitz et al. Pseudoidiopathic hypoparathyroidism: hypoparathyroidism with ineffective parathyroid hormone
BR9611815A (pt) Tablete de mascar com ação efervescente
Lagerlöf et al. Effects of inorganic orthophosphate and pyrophosphate on dissolution of calcium fluoride in water
Francis et al. Chemical agents in the control of calcification processes in biological systems
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
Tezvergil-Mutluay et al. Zoledronate and ion-releasing resins impair dentin collagen degradation
GB2195246A (en) Sustained release fluoride and calcium composition
Oh et al. Effect of zinc on the collagen degradation in acid-etched dentin
WO1999000135A1 (en) Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
US6160016A (en) Phosphorus binder
Pak et al. Effect of the oral administration of ammonium chloride, sodium phosphate, cellulose phosphate and parathyroid extract on the activity product of brushite in urine
CN1053653C (zh) 新l－苏糖酸衍生物
CA2395530C (en) Calcium formate for use as a phosphorus binder and a dietary supplement
Park et al. Injectable polysaccharide microcapsules for prolonged release of minocycline for the treatment of periodontitis
JPS6393710A (ja) フッ素イオンとカルシウムの持続放出組成物

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20080225

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee